The prevalence of adult male hypogonadism is expected to increase demand for testosterone replacement therapy. In middle-aged males, the frequency of hypogonadism ranges from 2.1% to 12.8%, according to a 2016 report by the European Association of Urology. In Europe, symptoms of hypogonadism and low testosterone affect 2.1% to 5.7% of males between the ages of 40 and 79. Hypogonadism is more prevalent in older males, obese men, men with co-morbid illnesses, and men with poor health. Furthermore, according to the Therapeutic Advances of Urology Journal: 2016, testosterone rose to become one of the most widely prescribed medications in the United States in 2011. The prevalence of hypogonadism in T2DM patients was found to be 20.7%, according to a study published in the Indian Journal of Endocrinology and Metabolism in 2017. The study evaluated the testosterone insufficiency in 900 males with type II diabetes mellitus (T2DM). Additionally, a moderate percentage of T2DM patients had hypogonadism, with the majority of these individuals falling into the 50–59 year age range.
In 2021, the market for Testosterone Replacement Therapy was estimated to be worth USD 1.98 billion.
Prominent Companies of Testosterone Replacement Therapy Industry:
AbbVie, Inc.:
1. Pharmaceutical business AbbVie has a significant presence in oncology and immunology. Humira, the company's best-selling medication, accounts for about half of its current earnings. Early in 2013, the company was separated from Abbott. Allergan's latest acquisition has included a number of new cosmetic and women's health medications. Created in 2012. American headquarters in North Chicago.
Bayer AG:
2. A healthcare and agricultural conglomerate from Germany is called Bayer. Health care, which includes pharmaceutical medications, vitamins, and other consumer healthcare products, accounts for about half of the business's sales. With the addition of Monsanto, the company's crop science division, which already comprises seeds, insecticides, herbicides, and fungicides, has grown. Built in 1863. German headquarters are in Leverkusen. A business that specialises in external innovation drug research and development called Evotec and Bayer have been working together since 2012.
